Aim: To study the mode of inhibition of ONO-3708 and S-145, 2 antagonists of thromboxane A2 (TXA2) receptors, against the rabbit platelet shape change and aggregation induced by stable analogue of TXA2 (STA2).
Methods: The platelet shape change and aggregation were quantified by the light transmission through platelet-rich plasma (PRP) and the intracellular calcium concentration ([Ca2+]i) was measured by fluorescence and imaging.
Results: (1) In PRP, STA2 (3 mumol.L-1)-induced aggregation was inhibited by egtazic acid 3 mmol.L-1, ONO-3708 300 mumol.L-1, and S-145 1 mumol.L-1 (P < 0.01), but not by indometacin (Ind) 3 mumol.L-1. The shape change induced by STA2 was inhibited only by S-145 in a concentration-dependent manner. S-145 1 and 3 mumol.L-1 were required to inhibit the shape change and aggregation. (2) The inhibitory effect of S-145, but not ONO-3708, was increased along with the prolongation of preincubation. (3) ONO-3708 lost the inhibitory effect on STA2-induced aggregation after washing, while the inhibitory effect of S-145 was enhanced by prolongation of preincubation and remained after washing. (4) STA2 3 mumol.L-1-induced [Ca2+]i mobilization was unaffected by Ind, partially reduced by ONO-3708 and egtazic acid 3 mmol.L-1 (P < 0.01), but completely inhibited by S-145 (P < 0.01).
Conclusion: S-145 and ONO-3708 were bound to a different site of the TXA2 receptor.